FTO and link to AML and breast cancer treatment, page-18

That's what I think.

Except they are snookered by RACE's patents.

COH started looking at brequinar but there are significant practicality problems with using it:

https://hotcopper.com.au/posts/46767728/single

... the other FTO inhibitor, brequinar, failed in the clinic. While it failed as an anticancer agent (it was used in more than 250 patients), it also failed as an transplant organ rejection drug (it is very immunosuppressive). One of the major reasons it never made it to market as an anti-rejection drug is the plasma concentrations of brequinar varied enormously (about 10 fold) depending on the patient. They found that they had to adjust the dosing on a per patient basis by assaying the patient's blood. This makes it totally impractical to use in regular clinical practice and hence why it was likely dropped.
​